Recent advances in Takayasu arteritis
Chikashi Terao1, Hajime Yoshifuji, Tsuneyo Mimori
1Center for Genomic Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.
International Journal of Rheumatic Diseases
|February 20, 2014
Summary
Takayasu arteritis (TAK) research identifies new genetic links and biomarkers. Advances in understanding pathophysiology and disease activity assessment promise improved patient management for this rare vasculitis.
Area of Science:
- Immunology
- Genetics
- Rheumatology
Background:
- Takayasu arteritis (TAK) is a rare systemic vasculitis affecting major arteries.
- Global patient distribution contrasts with higher prevalence in Asia, complicating research.
- Limited patient numbers hinder large-scale studies.
Purpose of the Study:
- To review recent advancements in understanding TAK pathophysiology and genetics.
- To highlight novel biomarkers and assessment tools for TAK disease activity.
- To discuss emerging treatment strategies for refractory TAK.
Main Methods:
- Review of recent genetic association studies.
- Analysis of novel biomarker research (e.g., pentraxin 3).
- Examination of new disease activity scoring systems (e.g., ITAS).
- Summary of biological agent treatment outcomes for refractory cases.
Main Results:
- Identification of susceptibility genes (IL12B, MLX, FCGR2A/3A) and HLA alleles (HLA-B*52:01, *67:01).
- Pentraxin 3 proposed as a biomarker; ITAS scoring system developed for disease activity.
- Successful use of biologics targeting TNF and IL-6R in refractory TAK.
Conclusions:
- Recent genetic and pathophysiological insights are advancing TAK understanding.
- Novel biomarkers and standardized assessment tools are crucial for future research.
- Biological therapies offer new hope for managing refractory Takayasu arteritis.
Related Concept Videos
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
1.3K
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
1.3K
01:27Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
948
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
948
01:26Atherosclerosis III: Management
741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741
01:21Rheumatic Heart Disease III: Medical Management
544
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
544
01:17Pericarditis III: Medical Management
586
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
586
01:14Myocarditis III: Medical Management
343
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
343